The DOI matches its Crossref record; 46 of the 47 references it cites were found in a registry or an index.
Delaying the Empiric Treatment of Candida Bloodstream Infection until Positive Blood Culture Results Are Obtained: a Potential Risk Factor for Hospital Mortality
Open accessAbstract
Fungal bloodstream infections are associated with significant patient mortality and health care costs. Nevertheless, the relationship between a delay of the initial empiric antifungal treatment until blood culture results are known and the clinical outcome is not well established. A retrospective cohort analysis with automated patient medical records and the pharmacy database at Barnes-Jewish Hospital was conducted. One hundred fifty-seven patients with a Candida bloodstream infection were identified over a 4-year period (January 2001 through December 2004). Fifty (31.8%) patients died during hospitalization. One hundred thirty-four patients had empiric antifungal treatment begun after the results of fungal cultures were known. From the time that the first blood sample for culture that was positive was drawn, 9 (5.7%) patients received antifungal treatment within 12 h, 10 (6.4%) patients received antifungal treatment between 12 and 24 h, 86 (54.8%) patients received antifungal treatment between 24 and 48 h, and 52 (33.1%) patients received antifungal treatment after 48 h. Multiple logistic regression analysis identified Acute Physiology and Chronic Health Evaluation II scores (one-point increments) (adjusted odds ratio [AOR], 1.24; 95% confidence interval [CI], 1.18 to 1.31; P < 0.001), prior antibiotic treatment (AOR, 4.05; 95% CI, 2.14 to 7.65; P = 0.028), and administration of antifungal treatment 12 h after having the first positive blood sample for culture (AOR, 2.09; 95% CI, 1.53 to 2.84; P = 0.018) as independent determinants of hospital mortality. Administration of empiric antifungal treatment 12 h after a positive blood sample for culture is drawn is common among patients with Candida bloodstream infections and is associated with greater hospital mortality. Delayed treatment of Candida bloodstream infections could be minimized by the development of more rapid diagnostic techniques for the identification of Candida bloodstream infections. Alternatively, increased use of empiric antifungal treatment in selected patients at high risk for fungal bloodstream infection could also reduce delays in treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Finally, in a study of 10,811 patients treated in four Utah hospitals, each hour delay in time from ED arrival to administration of antimicrobials was associated with 1.16 increased odds of in-hospital and 1.10 increased odds of 1-year mortality (1.13 in patients with hypotension vs 1.09 in patients without hypotension) (111).”
From Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. (2021) · cites this paper as [111]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Observational studies do, however, suggest that mortality may increase after intervals exceeding 3-5 hours from hospital arrival and/or sepsis recognition (98,111,119,120).”
From Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. (2021) · cites this paper as [111]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As mentioned previously, diagnosis of invasive candidiasis and candidemia remains a great challenge, since symptoms and signs are usually non-specific, microbiological cultures are difficult to analyze, and histological specimens require invasive procedures [29,30,46].”
From Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: part I. Epidemiology and diagnosis (2009) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Attributable mortality from IC remains high and increases with delays in treatment.”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [136]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Blood cultures take an average of 2–3 days to grow Candida, or longer depending on the species.”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [136]
Experimental — accuracy not yet measured
In the citing paper
“Some observational studies suggested that prompt initiation of appropriate empiric antifungal therapy may be associated with a reduction in mortality, however these studies do not prove a causal relationship between antifungal therapy and outcome, nor do they clarify the role of timing of treatment, and some other studies have failed to show this association [167, 171–173].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [173]
In the citing paper
“Another single-center retrospective cohort of 157 consecutive patients with a Candida BSI showed a trend toward improved survival when appropriate antifungal therapy was administered within 12 hours of blood culture collection (mortality 11.1% vs 33.1%; P 5 .169).45”
From Fungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting (2011) · cites this paper as [45]
In the citing paper
“In multivariate analysis the odds of death was 2-fold higher if adequate therapy was delayed more than 12 hours (P 5 .018).”
From Fungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting (2011) · cites this paper as [45]
In the citing paper
“Invasive candidiasis occurs frequently in hospitalized patients, and is associated with high mortality rates due to delays in recognition and initiation of appropriate antifungals.”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [70]
In the citing paper
“There is extensive clinical evidence that delayed initiation of appropriate antifungal treatment is associated with increased mortality in patients with invasive candidiasis [70,71,72].”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [70]
In the citing paper
“Mortality rates are estimated to be as high as 45% [16], probably due to inefficient diagnostic methods and inappropriate initial antifungal therapies [17].”
From Candida Infections, Causes, Targets, and Resistance Mechanisms: Traditional and Alternative Antifungal Agents (2013) · cites this paper as [17]
In the citing paper
“The Clinical and Laboratory Standards Institute (CLSI) Subcommittee for Antifungal Testing has developed standardized broth microdilution (BMD) (169) and disk diffusion (170) methods for in vitro susceptibility testing of Candida spp.”
From Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem (2007) · cites this paper as [170]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Knaus, W. A., Draper, E. A., Wagner, D. P., & Zimmerman, J. E. (1985) · Critical Care Medicine · doi:10.1097/00003246-198510000-00009 · Cited by 15,518
APACHE II-A Severity of Disease Classification System
Knaus, W. A., Draper, E. A., Wagner, D. P., & Zimmerman, J. E. (1986) · Critical Care Medicine · doi:10.1097/00003246-198608000-00028 · Cited by 13,379
APACHE II: a severity of disease classification system.
Knaus, W. A., Draper, E. S., Wagner, D. P., & Zimmerman, J. E. (1985) · PubMed · Cited by 6,034
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496
Inadequate Antimicrobial Treatment of Infections
Kollef, M. H., Sherman, G., Ward, S., & Fraser, V. J. (1999) · Chest · doi:10.1378/chest.115.2.462 · Cited by 1,805
Self-citationIbrahim, E. H., Sherman, G., Ward, S., Fraser, V. J., & Kollef, M. H. (2000) · Chest · doi:10.1378/chest.118.1.146 · Cited by 1,779
Self-citationComparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021585 · Cited by 1,380
Weinstein, M. P., Towns, M., Quartey, S. M., Mirrett, S., Reimer, L. G., Parmigiani, G., & Reller, L. B. (1997) · Clinical Infectious Diseases · doi:10.1093/clind/24.4.584 · Cited by 1,225
Secular Trends in the Epidemiology of Nosocomial Fungal Infections in the United States, 1980-1990
Beck‐Sagué, C. M., Jarvis, W. R., & System, N. N. I. S. (1993) · The Journal of Infectious Diseases · doi:10.1093/infdis/167.5.1247 · Cited by 1,140
The Risk of Determining Risk with Multivariable Models
Concato, J., Feinstein, A. R., & Holford, T. R. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-118-3-199302010-00009 · Cited by 1,129
Cited by
Sorted by citations
Items 301–400 of 1,000
Early Antimicrobial Therapy in Severe Sepsis and Septic Shock
Kumar, A. (2010) · Current Infectious Disease Reports · doi:10.1007/s11908-010-0128-x · Cited by 59
Impact of tolerance to fluconazole on treatment response in Candida albicans bloodstream infection
Levinson, T., Dahan, A., Novikov, A., Paran, Y., Berman, J., & Ben‐Ami, R. (2021) · Mycoses · doi:10.1111/myc.13191 · Cited by 50
Exposure of Candida albicans β (1,3)-glucan is promoted by activation of the Cek1 pathway
Chen, T., Jackson, J. W., Tams, R. N., Davis, S. E., Sparer, T. E., & Reynolds, T. B. (2019) · PLOS Genetics · doi:10.1371/journal.pgen.1007892 · Cited by 56
Camargo, J. F., Ahmed, A. A., Lindner, M. S., Morris, M. I., Anjan, S., Anderson, A. D., Prado, C. E., Dalai, S. C., Martínez, O., & Komanduri, K. V. (2020) · F1000Research · doi:10.12688/f1000research.19766.4 · Cited by 56
Lohmann, C., Sabou, M., Moussaoui, W., Prévost, G., Delarbre, J.-M., Candolfi, E., Gravet, A., & Letscher‐Bru, V. (2013) · Journal of Clinical Microbiology · doi:10.1128/jcm.03268-12 · Cited by 56
Pondérand, L., Pavèse, P., Maubon, D., Giraudon, E., Girard, T., Landelle, C., Maurin, M., & Caspar, Y. (2020) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-020-00403-w · Cited by 58
Sheppard, D. C., Locas, M., Restieri, C., & Laverdière, M. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.01113-08 · Cited by 58
The Economic Impact of Rapid Candida Species Identification by T2Candida Among High-Risk Patients
Bilir, S. P., Ferrufino, C. P., Pfaller, M. A., & Munakata, J. (2015) · Future Microbiology · doi:10.2217/fmb.15.29 · Cited by 55
Mortality and risk factor analysis for Candida blood stream infection: A multicenter study
Kato, H., Yoshimura, Y., Suido, Y., Shimizu, H., Ide, K., Sugiyama, Y., Matsuno, K., & Nakajima, H. (2019) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2019.01.002 · Cited by 59
Candida Peritonitis: An Update on the Latest Research and Treatments
Carneiro, H. A., Mavrakis, A., & Mylonakis, E. E. (2011) · World Journal of Surgery · doi:10.1007/s00268-011-1305-2 · Cited by 56
Propargyl-Linked Antifolates are Dual Inhibitors of Candida albicans and Candida glabrata
G-Dayanandan, N., Paulsen, J. L., Viswanathan, K., Keshipeddy, S. K., Lombardo, M. N., Zhou, W., Lamb, K. M., Sochia, A. E., Alverson, J. B., Priestley, N. D., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401916j · Cited by 54
Saraçlı, M. A., Fothergill, A. W., Sutton, D. A., & Wiederhold, N. P. (2015) · Medical Mycology · doi:10.1093/mmy/myv046 · Cited by 54
Diagnosis and Treatment of Candidemia in the Intensive Care Unit
Bassetti, M., Giacobbe, D. R., Vena, A., & Wolff, M. (2019) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0039-1693704 · Cited by 56
Zhang, F., Chen, J., Huang, H., Deng, X., Zhang, W., Zeng, M., Liu, R., Dai, L., & Wan, Q. (2021) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-021-04254-x · Cited by 54
Tumbarello, M., Sanguinetti, M., Trecarichi, E. M., La Sorda, M., Rossi, M., de Carolis, E., de Gaetano Donati, K., Fadda, G., Cauda, R., & Posteraro, B. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn381 · Cited by 53
Szabo, E. K., & MacCallum, D. M. (2011) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.2011.02262.x · Cited by 59
Amphotericin B in the Era of New Antifungals: Where Will It Stand?
Akinosoglou, K., Rigopoulos, E. A., Papageorgiou, D., Schinas, G., Polyzou, E., Dimopoulou, E., Gogos, C. A., & Dimοpoulos, G. (2024) · Journal of Fungi · doi:10.3390/jof10040278 · Cited by 59
Chen, P., Chuang, Y., Wang, J., Sheng, W., Yu, C., Chu, C.-C., Hsueh, P., Chang, S., & Chen, Y. (2012) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2012.08.025 · Cited by 53
Invasive Fungal Infections in the ICU
Shoham, S., & Marwaha, S. (2009) · Journal of Intensive Care Medicine · doi:10.1177/0885066609355262 · Cited by 55
Diagnostic Performance of T2Candida Among ICU Patients With Risk Factors for Invasive Candidiasis
Arendrup, M. C., Andersen, J. S., Holten, M., Krarup, K. B., Reiter, N., Schierbeck, J., & Helleberg, M. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofz136 · Cited by 53
Candidaemia and a risk predictive model for overall mortality: a prospective multicentre study
Keighley, C., Chen, S. C. A., Marriott, D. J. E., Pope, A. L., Chapman, B., Kennedy, K., Bak, N., Underwood, N., Wilson, H. L., McDonald, K., et al. (2019) · BMC Infectious Diseases · doi:10.1186/s12879-019-4065-5 · Cited by 52
Wang, H., Liu, N., Yin, M., Han, H., Yue, J., Zhang, F., Shan, T., Guo, H., & Wu, D. (2014) · BMC Infectious Diseases · doi:10.1186/s12879-014-0609-x · Cited by 54
Diagnostic challenges and recent advances in the early management of invasive fungal infections
Chandrasekar, P. H. (2009) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2009.01391.x · Cited by 52
Impact of Inactive Empiric Antimicrobial Therapy on Inpatient Mortality and Length of Stay
Scarsi, K. K., Feinglass, J. M., Scheetz, M. H., Postelnick, M. J., Bolon, M. K., & Noskin, G. A. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00466-06 · Cited by 52
Fungal bloodstream infections in tertiary care hospitals in Colombia
Cortés, J. A., Reyes, P., Gómez, C., Buitrago, G., & Leal, A. L. (2011) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2010.12.002 · Cited by 53
How much European prescribing physicians know about invasive fungal infections management?
Valerio, M., Vena, A., Bouza, E., Reiter, N., Viale, P., Hochreiter, M., Giannella, M., Muñóz, P., & on behalf the COMIC study group (Collaborative group on Mycosis) (2015) · BMC Infectious Diseases · doi:10.1186/s12879-015-0809-z · Cited by 50
the study group Candida albicans Germ Tube Antibody Detection in Critically Ill Patients (CAGTAUCI), Pemán, J., Zaragoza, R., Quindós, G., Alkorta, M., Cuétara, M. S., Camarena, J. J., Ramírez, P., Giménez, M. J., Martín‐Mazuelos, E., et al. (2011) · BMC Infectious Diseases · doi:10.1186/1471-2334-11-60 · Cited by 51
Kato, H., Yoshimura, Y., Suido, Y., Ide, K., Sugiyama, Y., Matsuno, K., & Nakajima, H. (2018) · Infection · doi:10.1007/s15010-018-1163-z · Cited by 51
Rautemaa‐Richardson, R., Rautemaa, V., Al-Wathiqi, F., Moore, C. B., Craig, L., Felton, T., & Muldoon, E. G. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky360 · Cited by 50
Candida Bloodstream Infections: Changes in Epidemiology and Increase in Drug Resistance
Kotey, F. C. N., Dayie, N. T. K. D., Tetteh‐Quarcoo, P. B., & Donkor, E. S. (2021) · Infectious Diseases Research and Treatment · doi:10.1177/11786337211026927 · Cited by 55
Whibley, N., Jaycox, J. R., Reid, D. M., Garg, A. V., Taylor, J. A., Clancy, C. J., Nguyen, M. H., Biswas, P. S., McGeachy, M. J., Brown, G. D., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500870 · Cited by 51
Candidemia: species involved, virulence factors and antimycotic susceptibility.
Luca, C. D., Guglielminetti, M. L., Ferrario, A., Calabr, M., & Casari, E. (2012) · PubMed · Cited by 49
Savage, R., Fowler, R., Rishu, A. H., Bagshaw, S. M., Cook, D., Dodek, P., Hall, R., Kumar, A., Lamontagne, F., Lauzier, F., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154944 · Cited by 49
Perlin, D. S., & Wiederhold, N. P. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix121 · Cited by 51
Pfaller, M. A., Carvalhaes, C. G., Smith, C. J., Diekema, D. J., & Castanheira, M. (2020) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2020.115016 · Cited by 52
Blood Gene Expression Signatures Predict Invasive Candidiasis
Zaas, A. K., Aziz, H., Lucas, J., Perfect, J. R., & Ginsburg, G. S. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000715 · Cited by 48
Dudiuk, C., Gamarra, S., Leonardeli, F., Jimenez-Ortigosa, C., Vitale, R. G., Afeltra, J., Perlin, D. S., & Garcia-Effron, G. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.01038-14 · Cited by 50
Epidemiology of Sepsis in Surgical Patients
Moore, L. J., & Moore, F. A. (2012) · Surgical Clinics of North America · doi:10.1016/j.suc.2012.08.009 · Cited by 48
T2 Magnetic Resonance Assay: Overview of Available Data and Clinical Implications
Zacharioudakis, I. M., Zervou, F. N., & Mylonakis, E. E. (2018) · Journal of Fungi · doi:10.3390/jof4020045 · Cited by 49
Szerencsés, B., Igaz, N., Tóbiás, Á., Prucsi, Z., Rónavári, A., Bélteky, P., Madarász, D., Papp, C., Makra, I., Vágvölgyi, C., et al. (2020) · BMC Microbiology · doi:10.1186/s12866-020-01858-9 · Cited by 48
Zhong, L., Zhang, S., Tang, K., Zhou, F., Zheng, C., Zhang, K., Cai, J., Zhou, H., Wang, Y., Tian, B., et al. (2020) · BMC Infectious Diseases · doi:10.1186/s12879-020-05536-z · Cited by 48
Chen, Y.-L., Kauffman, S., & Reynolds, T. B. (2008) · Infection and Immunity · doi:10.1128/iai.01514-07 · Cited by 47
Rahi, M. S., Jindal, V., Pednekar, P., Parekh, J., Gunasekaran, K., Sharma, S., Stender, M., & Jaiyesimi, I. A. (2021) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361211039050 · Cited by 50
ten Oever, J., Netea, M. G., & Kullberg, B. J. (2015) · Journal of Infection · doi:10.1016/j.jinf.2015.09.007 · Cited by 47
Hsueh, P., Graybill, J. R., Playford, E. G., Watcharananan, S. P., Oh, M., Jaalam, K., Huang, S., Nangia, V., Kurup, A., & Padiglione, A. A. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2009.03.014 · Cited by 48
Comparison of albicans vs. non-albicans candidemia in French intensive care units
Leroy, O., Mira, J. P., Montravers, P., Gangneux, J., Lortholary, O., & the AmarCand Study Group (2010) · Critical Care · doi:10.1186/cc9033 · Cited by 46
Spontaneous fungal peritonitis: Epidemiology, current evidence and future prospective
Fiore, M., & Leone, S. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i34.7742 · Cited by 47
Candidemia and invasive candidiasis among hospitalized neonates and pediatric patients
Harrington, R. L., Kindermann, S. L., Hou, Q., Taylor, R. J., Azie, N. E., & Horn, D. L. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1354824 · Cited by 49
Emerging Issues in Antifungal Resistance
Perfect, J. R., & Ghannoum, M. A. (2020) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2020.05.003 · Cited by 44
Camargo, J. F., Ahmed, A. A., Lindner, M. S., Morris, M. I., Anjan, S., Anderson, A. D., Prado, C. E., Dalai, S. C., Martínez, O., & Komanduri, K. V. (2019) · F1000Research · doi:10.12688/f1000research.19766.3 · Cited by 47
Pfaller, M. A., Boyken, L. B., Hollis, R. J., Kroeger, J. S., Messer, S. A., Tendolkar, S., & Diekema, D. J. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.01391-08 · Cited by 47
Trends in antifungal use in US hospitals, 2006–12
Vallabhaneni, S., Baggs, J., Tsay, S., Srinivasan, A. R., Jernigan, J. A., & Jackson, B. R. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky270 · Cited by 45
Fungi-on-a-Chip: microfluidic platforms for single-cell studies on fungi
Richter, F., Bindschedler, S., Calonne-Salmon, M., Declerck, S., Junier, P., & Stanley, C. E. (2022) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuac039 · Cited by 46
Poissy, J., Sendid, B., Damiens, S., Ishibashi, K. I., François, N., Kauv, M., Favory, R., Mathieu, D., & Poulain, D. (2014) · Critical Care · doi:10.1186/cc13953 · Cited by 49
Glöckner, A. (2011) · European journal of medical research · doi:10.1186/2047-783x-16-4-167 · Cited by 46
Boonstra, J., van der Elst, K. C. M., Veringa, A., Jongedijk, E. M., Brüggemann, R. J. M., Koster, R. A., Kampinga, G. A., Kosterink, J. G. W., van der Werf, T. S., Zijlstra, J. G., et al. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01398-17 · Cited by 47
Is Candida really a threat in the ICU?
Blot, S. I., Dimopoulos, G., Rello, J., & Vogelaers, D. (2008) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e32830f1dff · Cited by 46
Li, C.-H., Yang, R., Pang, J. S., Chang, S.-S., Lin, C., Chen, C.-H., Chen, H., & Chiu, T. (2011) · Academic Emergency Medicine · doi:10.1111/j.1553-2712.2010.00991.x · Cited by 45
Playford, E. G., Lipman, J., Jones, M., Lau, A. F., Kabir, M., Chen, S. C. ‐., Marriott, D. J. E., Seppelt, I., Gottlieb, T., Cheung, W., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw610 · Cited by 45
Zhang, S. X., Carroll, K. C., Lewis, S., Totten, M., Mead, P. A., Samuel, L. P., Steed, L. L., Nolte, F. S., Thornberg, A., Reid, J. L., et al. (2020) · Journal of Clinical Microbiology · doi:10.1128/jcm.02096-19 · Cited by 45
Ostrosky‐Zeichner, L., Rex, J. H., Pfaller, M. A., Diekema, D. J., Alexander, B. D., Andes, D. R., Brown, S. D., Chaturvedi, V. P., Ghannoum, M. A., Knapp, C. C., et al. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00420-08 · Cited by 45
Mun, S. J., Kim, S., Kim, H., Moon, C., & Wi, Y. M. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07267-9 · Cited by 47
Acosta, J., Catalán, M., del Palacio‐Pérez‐Medel, Á., Montejo, J. C., de la Cruz, J., Moragues, M. D., Pontón, J., Finkelman, M., & del Palacio, A. (2011) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-011-1365-0 · Cited by 44
Paolucci, M., Stanzani, M., Melchionda, F., Tolomelli, G., Castellani, G., Landini, M. P., Varani, S., Lewis, R. E., & Sambri, V. (2012) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2012.10.012 · Cited by 44
Zimmerman, J. J., Sullivan, E. M., Yager, T. D., Cheng, C., Permut, L. C., Cermelli, S., McHugh, L. C., Sampson, D. L., Seldon, T. A., Brandon, R. B., et al. (2016) · Critical Care Medicine · doi:10.1097/ccm.0000000000002100 · Cited by 44
Kaur, R., Dhakad, M. S., Goyal, R., Haque, A., & Mukhopadhyay, G. (2016) · Journal of Global Infectious Diseases · doi:10.4103/0974-777x.192969 · Cited by 46
Zaragoza, R., Pemán, J., Quindós, G., Iruretagoyena, J. R., Cuétara, M. S., Ramírez, P., Gómez, M. D., Camarena, J. J., Viudes, A., & Pontón, J. (2009) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2009.02794.x · Cited by 44
Circulating galectin-3 in infections and non-infectious inflammatory diseases
ten Oever, J., Giamarellos‐Bourboulis, E. J., van de Veerdonk, F. L., Stelma, F. F., Simon, A., Janssen, M., Johnson, M. D., Pachot, A., Kullberg, B. J., Joosten, L., et al. (2013) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-013-1919-4 · Cited by 44
Mutschlechner, W., Risslegger, B., Willinger, B., Hoenigl, M., Bucher, B., Eschertzhuber, S., & Lass‐Flörl, C. (2015) · Transplantation · doi:10.1097/tp.0000000000000635 · Cited by 43
Update on the management of Candida infections in preterm neonates
Manzoni, P., Mostert, M., & Castagnola, E. (2015) · Archives of Disease in Childhood Fetal & Neonatal · doi:10.1136/archdischild-2012-303350 · Cited by 43
Tascini, C., Sozio, E., Corte, L., Sbrana, F., Scarparo, C., Ripoli, A., Bertolino, G., Merelli, M., Tagliaferri, E., Corcione, A., et al. (2017) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2017.1384956 · Cited by 45
Kim, S. J., Hwang, S. O., Kim, Y. W., Lee, J. H., & Cha, K. (2018) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2018.05.047 · Cited by 43
Zilberberg, M. D., & Shorr, A. F. (2009) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2009.04.008 · Cited by 42
Johnson, M. A., Cartmell, J., Weisser, N. E., Woods, R. J., & Bundle, D. R. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.355578 · Cited by 42
Prüller, F., Wagner, J., Raggam, R. B., Hoenigl, M., Kessler, H. H., Truschnig‐Wilders, M., & Krause, R. (2014) · Medical Mycology · doi:10.1093/mmy/myu023 · Cited by 42
Candidemia on presentation to the hospital: development and validation of a risk score
Shorr, A. F., Tabak, Y. P., Johannes, R. S., Sun, X., Spalding, J. R., & Kollef, M. H. (2009) · Critical Care · doi:10.1186/cc8110 · Cited by 43
Self-citationHerbrecht, R., Caillot, D., Cordonnier, C., Auvrignon, A., Thiébaut, A., Brethon, B., Michallet, M., Mahlaoui, N., Bertrand, Y., Preziosi, P., et al. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks266 · Cited by 43
Patch, M., Weisz, E. E., Cubillos, A. L., Estrada, S. J., & Pfaller, M. A. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky046 · Cited by 42
White, S., Schmidt, R. L., Walker, B. S., & Hanson, K. E. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009833.pub2 · Cited by 42
Playford, E. G., Eggimann, P., & Calandra, T. (2008) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e3283177967 · Cited by 42
Prophylaxis, empirical and preemptive treatment of invasive candidiasis
Playford, E. G., Lipman, J., & Sorrell, T. C. (2010) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e32833e10e8 · Cited by 41
Antifungal prophylaxis and pre-emptive therapy: When and how?
Sprute, R., Nacov, J. A., Neofytos, D., Oliverio, M., Prattes, J., Reinhold, I., Cornely, O. A., & Stemler, J. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101190 · Cited by 42
Sandherr, M., Stemler, J., Schalk, E., Hattenhauer, T., Hentrich, M., Hertenstein, B., Hohmann, C., Mellinghoff, S. C., Mispelbaum, R., Rieger, C. T., et al. (2025) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2025.101214 · Cited by 46
An Italian consensus for invasive candidiasis management (ITALIC)
Scudeller, L., Viscoli, C., Menichetti, F., Bono, V. D., Cristini, F., Tascini, C., Bassetti, M., & Viale, P. (2013) · Infection · doi:10.1007/s15010-013-0558-0 · Cited by 42
Zilberberg, M. D., Kothari, S., & Shorr, A. F. (2009) · Critical Care · doi:10.1186/cc7924 · Cited by 41
The Management of Severe Sepsis and Septic Shock
Morrell, M. R., Micek, S. T., & Kollef, M. H. (2009) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2009.04.002 · Cited by 41
Self-citationCornely, O. A., Sidhu, M., Odeyemi, I. A. O., van Engen, A., van der Waal, J. M., & Schoeman, O. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802124889 · Cited by 40
Lagunes, L., Rey-Perez, A., Martín-Gómez, M. T., Vena, A., de Egea, V., Muñóz, P., Bouza, E., Díaz‐Martín, A., Palacios-García, I., Garnacho‐Montero, J., et al. (2016) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-016-2775-9 · Cited by 41
Zaragoza, R., Perman, J., Salavert, M., Viudes, Solé, A., Jarque, I., Cantón, R., Monte‐Boquet, E., & Romá, E. (2008) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s3994 · Cited by 42
Increased presepsin levels are associated with the severity of fungal bloodstream infections
Bamba, Y., Moro, H., Aoki, N., Koizumi, T., Ohshima, Y., Watanabe, S., Sakagami, T., Koya, T., Takada, T., & Kikuchi, T. (2018) · PLoS ONE · doi:10.1371/journal.pone.0206089 · Cited by 39
TRIM31 facilitates K27-linked polyubiquitination of SYK to regulate antifungal immunity
Wang, X., Zhang, H., Shao, Z., Zhuang, W., Sui, C., Liu, F., Chen, X., Hou, J., Kong, L., Liu, H., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00711-3 · Cited by 40
Synthesis and antifungal activity of some substituted phenothiazines and related compounds
Sarmiento, G. P., Vitale, R. G., Afeltra, J., Moltrasio, G. Y., & Moglioni, A. G. (2010) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2010.10.019 · Cited by 40
Hope, W. W., Drusano, G. L., Moore, C. B., Sharp, J., Louie, A., Walsh, T. J., Denning, D. W., & Warn, P. A. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00601-06 · Cited by 40
Borghi, E., Iatta, R., Sciota, R., Biassoni, C., Cuna, T., Montagna, M. T., & Morace, G. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.00952-10 · Cited by 40
Epelbaum, O., Marinelli, T. M., Haydour, Q., Pennington, K. M., Evans, S. E., Carmona, E. M., Husain, S., Knox, K. S., Jarrett, B. J., Azoulay, É., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202410-2045st · Cited by 45
Initial treatment and outcome of Candida glabrata versus Candida albicans bloodstream infection
Klevay, M. J., Horn, D. L., Neofytos, D., Pfaller, M. A., & Diekema, D. J. (2009) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2009.03.007 · Cited by 40
On the Roles of Calcineurin in Fungal Growth and Pathogenesis
Chen, Y., Kozubowski, L., Cardenas, M. E., & Heitman, J. (2010) · Current Fungal Infection Reports · doi:10.1007/s12281-010-0027-5 · Cited by 39
Schuetz, A. N. (2013) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2013.03.009 · Cited by 39
Riedel, S. F., Eisinger, S. W., Dam, L. M., Stamper, P. D., & Carroll, K. C. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.02260-10 · Cited by 40
Montravers, P., Pérrigault, P.-F., Timsit, J., Mira, J. P., Lortholary, O., Leroy, O., Gangneux, J., Guillemot, D., Bensoussan, C., Bailly, S., et al. (2016) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2016.10.001 · Cited by 39
Metadata
- Authors
- Morrell, M., Fraser, V. J., & Kollef, M. H.
- Affiliations
- Washington University in St. Louis (US)
- Pulmonary and Critical Care Division
- Corresponding author
- Kollef, Marin H.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2005-09
- Volume
- 49
- Issue
- 9
- Pages
- 3640-3645
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC1195428
- OpenAlex
- W2137575148
- Cited by
- 1,286
- References
- 47
- Citations by year
- 2026: 33 · 2025: 33 · 2024: 41 · 2023: 33 · 2022: 53 · 2021: 51 · 2020: 58 · 2019: 63 · 2018: 65 · 2017: 67 · 2016: 71 · 2015: 77 · 2014: 97 · 2013: 75 · 2012: 78
- FWCI
- 27.08
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Infective Endocarditis Diagnosis and Management
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Keywords
- candidemia, fungemia, empirical antifungal therapy, treatment delay, blood culture, in-hospital mortality, APACHE II score, prior antibiotic use, rapid diagnostic tests
- MeSH terms
- Adult, Aged, Aged, 80 and over, Candidiasis, Cross Infection, Female, Humans, Male, Middle Aged, Retrospective Studies, Risk Factors, Cohort Studies, Logistic Models, Fungemia, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
